Consistent with this newly identified association between RALB and DR5, we have shown that inhibition of RALB through specific siRNA or the broad spectrum cyclin-dependent kinase inhibitor Dinaciclib significantly sensitised KRASMT CRC cells to TRAIL treatment. Here, RALB is linked to colorectal carcinoma.